MINNEAPOLIS & BARCELONA, Spain--(BUSINESS WIRE)--New data presented today at EuroPCR reports extensive experience on the safety and performance of Medtronic’s (NYSE: MDT) Endeavor Zotarolimus-Eluting Coronary Stent in routine clinical practice with a diverse patient population, providing in-practice alignment with results from the ENDEAVOR clinical trials.
